Get Pat To Post make money with your web site

  • Partner links

    • Avastin’s Breast Cancer Effect Modest ‘At Best’ (CME/CE)

    By Charles Bankhead, , MedPage TodayPublished: July 10, 2012Reviewed by Dori F. Zaleznik, MD; Associate Clinical Professor of Medicine, Harvard Medical School, Boston

    The angiogenesis inhibitor bevacizumab (Avastin) has “at best” a modest effect on outcomes in metastatic breast cancer, authors of a systematic review concluded.

    Despite statistically significant improvements in progression-free survival (33%) and response rate (15%), patients treated in first or second line with bevacizumab lived no longer than their counterparts treated without the targeted agent, according to Anna Dorothea Wagner, MD, of Vaudois University Hospital Center in Lausanne, Switzerland, and co-authors.

    Grade 3/4 adverse events and serious adverse events occurred significantly more often with bevacizumab, but treatment-related deaths occurred less often, the investigators reported in the July issue of the Cochrane Database of Systematic Reviews.

    “The overall patient benefit from adding bevacizumab to first- and second-line chemotherapy in metastatic breast cancer can at ideal be considered as modest,” they wrote in conclusion. “It is dependent on the type of chemotherapy used and limited to a prolongation of [progression-free survival] and response rates.”

    “In contrast, bevacizumab has no significant impact on the patient-related secondary outcomes of overall survival or quality of life, which indicate a direct patient benefit,” they added. “For this reason, the clinical value of bevacizumab for metastatic breast cancer remains controversial.”

    Multiple angiogenesis inhibitors have become available for cancer therapy in recent years, and many others have demonstrated activity in animal models of cancer. However, the benefits have tended to be heterogeneous and transient, both in preclinical and clinical settings, the authors wrote in their introduction.

    Results of some pivotal studies of angiogenesis inhibitors have been frankly disappointing, leaving the clinical value of the drug class in question, they continued.

    Wagner and colleagues sought to address some of the uncertainty by performing a systematic review of the safety and efficacy of therapies that target vascular endothelial growth factor (VEGF) in metastatic breast cancer.

    Investigators reviewed published literature and data from several sources to identify randomized controlled trials and nonrandomized studies of VEGF-targeted therapies. The search had a starting point of 2000 for all information collected.

    The search identified seven randomized trials and five on-going trials. Four of the published trials focused on VEGF-targeted therapy for metastatic breast cancer, all involving bevacizumab.

    The four trials included a total of 2,886 patients for comparison of chemotherapy with versus without bevacizumab. For first-line therapy, the analysis yielded a progression hazard ratio of 0.67 (95% CI 0.61 to 0.73) in favor of bevacizumab. Second-line therapy that included the angiogenesis inhibitor was associated with a progression hazard ratio of 0.85 (95% CI 0.73 to 0.98).

    The data also showed higher objective response rates in first- and second-line therapy when bevacizumab was added to chemotherapy.

    The addition of bevacizumab did not extend overall survival, as reflected in hazard ratios of 0.93 (95% CI 0.84 to 1.04) and 0.98 (95% CI 0.83 to 1.16) for first- and second-line therapy, respectively.

    Quality-of-life data were limited to four trials (two published) and did not show a significant impact of anti-VEGF therapy.

    Treatment with bevacizumab was associated with a 77% increase in the hazard for grade 3/4 adverse events (95% CI 1.44 to 2.18) and a 41% higher risk of serious adverse events (95% CI 1.13 to 1.75). However, treatment-related deaths occurred significantly less often in bevacizumab-treated patients (OR 0.60, 95% CI 0.36 to 0.99).

    The study received support from University Halle-Wittenberg in Germany and the German Ministry for Education and Research.

    Co-author Christoph Thomssen disclosed relationships with Roche.

    Working from Houston, home to one of the world’s largest medical complexes, has more than 20 years of experience as a medical writer and editor. His career began as a science and medical writer at an academic medical center. He later spent nearly a decade as a writer and editor for Medical World News, one of the leading medical trade magazines of its era. His byline has appeared in medical publications that have included Cardio, Cosmetic Surgery Times, Dermatology Times, Diagnostic Imaging, Family Practice, Journal of the National Cancer Institute, Medscape, Oncology News International, Oncology Times, Ophthalmology Times, Patient Care, Renal and Urology News, The Medical Post, Urology Times, and the International Medical News Group newspapers. He has a BA in journalism and MA in mass communications, both from Texas Tech University.

    Related News:


    Details :
    Submited at Wednesday, July 11th, 2012 at 12:15 am on Uncategorized by hilman
    Comment RSS 2.0 - leave a comment - trackback